Small cell lung cancer associated antigens and uses therefor

• US 7,314,721 B2
• Filed: 01/20/2004
• Issued: 01/01/2008
• Est. Priority Date: 01/21/2000
• Status: Expired due to Fees

• Current Assignee: Ludwig Institute for Cancer Research, Ltd., Memorial Sloan-Kettering Cancer Center, New York Hospital-Cornell Medical Center
• Original Assignee: Ludwig Institute for Cancer Research, Ltd., Memorial Sloan-Kettering Cancer Center, New York Hospital-Cornell Medical Center
• Inventors: Gure, Ali O., Jager, Dirk, Old, Lloyd J., Scanlan, Matthew J., Chen, Yao-Tseng, Stockert, Elisabeth
• Primary Examiner(s): Ungar; Susan
• Assistant Examiner(s): REDDIG, PETER J
• Application Number:
  US10/761,169
• Publication Number:
  US 20040126808A1
• Time in Patent Office: 1,442 Days
• Field of Search: 435/4, 435/6, 435/7.1
• US Class Current: 435/7.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: G01N 33/57423 of lung

Abstract

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in small cell lung cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with small cell lung cancer. The invention provides, among other things, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

Claims

1. A method for diagnosing cancer, comprising

contacting a biological sample isolated from a patient, who is suspected of having the cancer, with SOX1 (SEQ ID NO:

18) or ZIC2 (SEQ ID NO;

     22) and determining the presence or level of an antibody that binds SOX1 (SEQ ID NO;

     18) or ZIC2 (SEQ ID NO;

     22) or antibodies that bind SOX1 (SEQ ID NO;

     18) and ZIC2 (SEQ ID NO;

     22), wherein the presence or level of said antibody or antibodies is an indication that the subject has cancer, wherein the cancer is small cell lung cancer.

2. The method of claim 1, wherein the sample is a body fluid, a body effusion or a tissue.

3. The method of claim 2, wherein the sample is blood or serum.

4. The method of claim 1, wherein SOX1 (SEQ ID NO:

18) or ZIC2 (SEQ ID NO;

22) are detectably labeled.

5. The method of claim 4, wherein the detectably labeled SOX1 (SEQ ID NO:

18) or ZIC2 (SEQ ID NO;

22) is labeled with a radioactive label or an enzyme.

6. The method of claim 1, wherein the nucleic acid molecule is SOX1 (SEQ ID NO:

4).

7. The method of claim 1, wherein the nucleic acid molecule is ZIC2 (SEQ ID NO:

5).

8. The method of claim 1, wherein the sample is contacted with SOX1 (SEQ ID NO:

18) and ZIC2 (SEQ ID NO;

22).

9. The method of claim 1, wherein the sample is contacted with SOX1 (SEQ ID NO:

18).

10. The method of claim 1, wherein the sample is contacted with ZIC2 (SEQ ID NO:

22).